ArticleNature2024
Structure of the human dopamine transporter and mechanisms of inhibition.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- An updated systematic review and meta-analysis of modafinil for excessive daytime sleepiness in narcolepsy.Sleep medicine: X · 2026Review
- Structural basis of the transport mechanism of hBGT1.Cell discovery · 2026Article
- An updated review of enantioselective syntheses and biological actions of carbanucleosides.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- From dual norepinephrine-dopamine reuptake inhibition to selective dopamine reuptake inhibitors: a case of aromatically substitutedRSC medicinal chemistry · 2026Article
- Unraveling the enigma: Post-translational modifications in psychiatric disorders and their regulatory mechanisms.Journal of translational internal medicine · 2026Article
- An emerging role for synaptic ZnPharmacology & therapeutics · 2026Review
- Molecular insights into fungal inositol phosphorylceramide synthesis and its inhibition by antifungal aureobasidin A.Nature communications · 2026Article
- A reversible allosteric inhibitor of GlyT2 for neuropathic pain without on-target side effects.Nature communications · 2026Article
- Cell membrane cholesterol affects serotonin transporter efflux due to altered transporter oligomerization.Molecular psychiatry · 2026Article
- The radiotracer [Annals of nuclear medicine · 2026Review
- (N)-Methanocarba-adenosines as monoamine transporter allosteric inhibitors: Extended NEuropean journal of medicinal chemistry · 2026Article
- Modulation of monoaminergic neurotransmission in substance use disorders: a neuropharmacological perspective focusing on plant-derived metabolites.Frontiers in pharmacology · 2026Review
- Structural basis for pharmacotherapeutic action of triple reuptake inhibitors.Nature communications · 2025Article
- Mechanisms of transport and analgesic compounds recognition by glycine transporter 2.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Structural pharmacology of SV2A reveals an allosteric modulation mechanism in the major facilitator superfamily.Nature communications · 2025Article
- A reversible allosteric inhibitor of GlyT2 alleviates neuropathic pain without on-target side effects.bioRxiv : the preprint server for biology · 2025Article
- Modular RNA interactions shape FXR1 condensates involved in mRNA localization and translation.Nature communications · 2025Article
- Structural insights into the substrate uptake and inhibition of the human creatine transporter (hCRT).Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Cholecystokinin-expressing GABA neurons elicit long-term potentiation in the cortical inhibitory synapses and attenuate sound-shock associative memory.Scientific reports · 2025Article
- Repurposing drugs for the human dopamine transporter through WHALES descriptors-based virtual screening and bioactivity evaluation.Journal of pharmaceutical analysis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Dushyant Kumar SrivastavaVollum Institute, Oregon Health and Science University, Portland, OR, USA.
Vikas NavratnaVollum Institute, Oregon Health and Science University, Portland, OR, USA.
Dilip K ToshMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Audrey ChinnVollum Institute, Oregon Health and Science University, Portland, OR, USA.
Md Fulbabu SkTheoretical and Computational Biophysics Group, NIH Center for Macromolecular Modeling and Visualization, Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Emad TajkhorshidTheoretical and Computational Biophysics Group, NIH Center for Macromolecular Modeling and Visualization, Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID 0000-0001-8434-1010
Kenneth A JacobsonMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. kennethj@niddk.nih.gov.ORCID 0000-0001-8104-1493
Eric GouauxVollum Institute, Oregon Health and Science University, Portland, OR, USA. gouauxe@ohsu.edu.ORCID 0000-0002-8549-2360
Funding
Pacific Northwest Center for Cryo-EM - Screening supplementU24GM129547 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI EVANS, JAMES E, GOUAUX, JAMES E · 2018 to 2023
$54.8MWHOLE CELL SIMULATIONP41GM104601 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI SCHULTEN, KLAUS · 2012 to 2021
$19.0MResource for Macromolecular Modeling and VisualizationR24GM145965 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Emad Tajkhorshid · 2022 to 2026
$6.2MStructure and Function of Neurotransmitter TransportersR01MH070039 · NIMH · OREGON HEALTH & SCIENCE UNIVERSITY · PI GOUAUX, JAMES E · 2004 to 2024
$4.1MDevelopment of Drugs Acting at Ion ChannelsZIADK031127 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 2009 to 2025
$3.9MInductively Coupled Plasma Mass Spectrometer for High Sensitivity Elemental AnalysisS10OD028492 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI RALLE, MARTINA · 2021 to 2021
$336kIntramural NIH HHS ZIA DK031127NIGMS NIH HHS P41 GM104601NIGMS NIH HHS R24 GM145965NIGMS NIH HHS U24 GM129547NIH HHS S10 OD028492NIMH NIH HHS R01 MH070039
Abstract
The neurotransmitter dopamine has central roles in mood, appetite, arousal and movement
Indexed as
Dopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsAllosteric SiteCocaineCryoelectron MicroscopyDopamineHumansModels, MolecularMovementProtein ConformationZinc(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl esterCocaineDopamineDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsZinc
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.